Pulmatrix‘s branded generic of Spiriva HandiHaler, called PUR0200, was shown to promote similar improvements in lung function in patients with chronic obstructive pulmonary disease (COPD), but at significantly lower doses than Spiriva, according to a Phase 1 clinical trial. The study reporting the findings is titled “The pharmacokinetics,…
The surgical removal of tonsils and adenoids, a common procedure in children, has been linked to an increased risk of respiratory infectious diseases, particularly chronic obstructive pulmonary disease (COPD), a new study reports. The study, “Association of Long-Term Risk of Respiratory, Allergic, and Infectious Diseases With Removal of Adenoids…
A patient-satisfaction survey found that the uni-flo2 single-nasal cannula system (Uni-flo2) is considered to be comfortable, stable and secure by 98 percent of those who responded, the system’s developers reported in a press release. Uni-flo2 is designed to ensure continuous oxygen flow, equivalent to the low-flow, dual-pronged cannula…
The investigational monoclonal antibody Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), top-line results of the Phase 3 TERRANOVA trial have shown. The disappointing results follow previously announced data from the Phase 3 GALATHEA trial that also showed the candidate…
A newly developed tool can predict patients with chronic obstructive pulmonary disease (COPD) who are at a high risk of hospitalization due to a disease flare-up, according to a study. The new Laboratory-based Intermountain Validated Exacerbation, or LIVE, score identifies patients who may benefit from early intervention to avoid hospitalization…
Combining home oxygen therapy (HOT) with home noninvasive ventilation (HMV) could be more effective and less expensive than HOT alone for certain patients with chronic obstructive pulmonary disease (COPD), a study suggests. Sponsored by the health technology company Royal Philips, the study offers an economic analysis showing potential…
The Zephyr Endobronchial Valve, Pulmonx’s minimally invasive treatment for severe emphysema, was recently found to improve breathing, quality of life, and activity for patients in a U.S. clinical trial called LIBERATE. The treatment met all of the trial’s primary and secondary endpoints, or goals, after one year. Emphysema is a…
A new study showed that 21% of chronic obstructive pulmonary disease (COPD) cases can be attributed to occupational exposures, particularly exposure to biological dust, pesticides, gases, and fumes. The study, “Occupational exposures and 20-year incidence of COPD: the European Community Respiratory Health Survey,” was published in the…
Top-line results of a Phase 3 trial showed that treatment candidate Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), AstraZeneca and its subsidiary MedImmune announced. The multi-center, double-blind GALATHEA (NCT02138916) study is part of AstraZeneca’s VOYAGER…
Verona Pharma’s treatment candidate for chronic obstructive pulmonary disease (COPD) RPL554 works to open the airways of the lungs, aiding bronchodilation, when used with Spiriva (tiotropium), and its newer inhaled formulation is safe and appropriate for patient use, clinical trial data being presented at ATS 2018 report. RPL554 is designed…
Get regular updates to your inbox.